Corvus Pharmaceuticals CRVS Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $40.1M+776% | $4.58M+59.6% | $2.87M-80.5% | $14.69M+194% | $5M-42.8% | ||
| $196.61M+277% | $52.17M— | —— | —— | —— | ||
| $43K+16.2% | $37K+15.6% | $32K-62.8% | $86K+8.9% | $79K+5.3% | ||
| $3.19M+123% | $1.43M+16.7% | $1.22M-5.0% | $1.29M+7.2% | $1.2M-49.3% | ||
| $239.95M+312% | $58.21M-13.0% | $66.94M-11.7% | $75.78M+66.6% | $45.49M-16.4% | ||
| $282K+28.2% | $220K-0.5% | $221K-11.2% | $249K+50.9% | $165K+9.3% | ||
| $751K-10.5% | $839K-9.5% | $927K-8.4% | $1.01M-7.6% | $1.1M-7.0% | ||
| $1.72M+101% | $855K+0.4% | $852K+36.1% | $626K-0.5% | $629K-0.5% | ||
| $10.5M-4.5% | $10.99M-4.7% | $11.53M-2.2% | $11.79M-2.2% | $12.06M-3.8% | ||
| $253.2M+256% | $71.12M-11.6% | $80.47M-10.0% | $89.46M+50.5% | $59.44M-13.7% | ||
| $4.7M+88.6% | $2.49M+26.2% | $1.97M-37.1% | $3.14M+140% | $1.31M-49.3% | ||
| $6.99M+7.7% | $6.49M+13.4% | $5.72M+14.1% | $5.01M+29.5% | $3.87M+3.9% | ||
| $428K+6.2% | $403K+6.3% | $379K+6.8% | $355K+11.3% | $319K+72.4% | ||
| $12.11M+29.1% | $9.38M+16.2% | $8.07M-5.1% | $8.51M-8.3% | $9.28M-73.8% | ||
| $406K-24.0% | $534K-15.5% | $632K-13.2% | $728K-12.7% | $834K-11.0% | ||
| $12.52M+26.2% | $9.91M+13.9% | $8.71M-5.7% | $9.23M-8.7% | $10.11M-72.2% | ||
| —— | —— | —— | —— | —— | ||
| $8K+14.3% | $7K0.0% | $7K0.0% | $7K0.0% | $7K0.0% | ||
| $667.78M+40.8% | $474.39M+0.3% | $472.79M+0.3% | $471.18M+9.0% | $432.39M+0.4% | ||
| -$425.99M-3.3% | -$412.29M-3.1% | -$399.97M-2.6% | -$389.82M-2.1% | -$381.82M+3.8% | ||
| -$1.13M-25.7% | -$896K+15.5% | -$1.06M+7.7% | -$1.15M+8.5% | -$1.25M+2.6% | ||
| $240.68M+293% | $61.21M-14.7% | $71.77M-10.5% | $80.23M+62.7% | $49.33M+51.5% | ||
| $253.2M+256% | $71.12M-11.6% | $80.47M-10.0% | $89.46M+50.5% | $59.44M-13.7% | ||
| $196.61M+277% | $52.17M— | —— | —— | —— | ||
| $1.72M+101% | $855K+0.4% | $852K+36.1% | $626K-0.5% | $629K-0.5% | ||
| $751K-10.5% | $839K-9.5% | $927K-8.4% | $1.01M-7.6% | $1.1M-7.0% | ||
| $751K-10.5% | $839K-9.5% | $927K-8.4% | $1.01M-7.6% | $1.1M-7.0% | ||
| $1.72M+101% | $855K+0.4% | $852K+36.1% | $626K-0.5% | $629K-0.5% | ||
| $751K-10.5% | $839K-9.5% | $927K-8.4% | $1.01M-7.6% | $1.1M-7.0% | ||
| $1.72M+101% | $855K+0.4% | $852K+36.1% | $626K-0.5% | $629K-0.5% | ||
| $6.99M+7.7% | $6.49M+13.4% | $5.72M+14.1% | $5.01M+29.5% | $3.87M+3.9% | ||
| $6.99M+7.7% | $6.49M+13.4% | $5.72M+14.1% | $5.01M+29.5% | $3.87M+3.9% | ||
| $834K-11.0% | $937K-7.3% | $1.01M-6.6% | $1.08M-6.1% | $1.15M+2.8% | ||
| $8K+14.3% | $7K0.0% | $7K0.0% | $7K0.0% | $7K0.0% | ||
| $10.5M-4.5% | $10.99M-4.7% | $11.53M-2.2% | $11.79M-2.2% | $12.06M-3.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Corvus Pharmaceuticals's total assets?
- Corvus Pharmaceuticals (CRVS) holds $253.2M in total assets, up 326.0% year over year.
- How much debt does Corvus Pharmaceuticals have?
- Corvus Pharmaceuticals carries $834.0K in total debt against $240.7M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Corvus Pharmaceuticals have?
- Corvus Pharmaceuticals holds $40.1M in cash and equivalents.
- Can Corvus Pharmaceuticals cover its short-term obligations?
- Its current ratio is 19.81 — current assets exceed current liabilities.
- Where does Corvus Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.